Diss. (sammanfattning) Stockholm : Karol. inst. / Härtill 5 uppsatser.

Thesis (Ph. D.)--School of Pharmacy and Dept. of Chemistry. University of Missouri--Kansas City, 2008. / "A dissertation in pharmaceutical sciences and chemistry." Advisor: Ashim K. Mitra. Typescript. Vita. Description based on contents viewed Sept. 12, 2008; title from "catalog record" of the print edition. Includes bibliographical references (leaves 136-142). Online version of the print edition.

Diss. (sammanfattning) Stockholm : Karol. inst., 2006. / Härtill 4 uppsatser.

Thesis (Ph.D.)--University of Minnesota, 1999. / Includes bibliographical references. Also available on the World Wide Web as a PDF file.

A thesis submitted to the Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, in fulfilment of the requirements for the degree of Doctor of Philosophy, Department of Pharmacy and Pharmacology, University of the Witwatersrand, Johannesburg, 2017. / Numerous pharmaceutical solid dosage form manufacturing techniques have emerged over the years and among them, 3D-Printing (3DP) has emerged as a highly attractive and versatile approach. 3DP is a cutting edge technology set to expand and revolutionize tablet manufacturing among various other applications in industry. The study reported in this thesis focuses on developing a humic acid-polyquaternium-10 (HA-PQ10) 3D-Printable ink for the delivery of three anti-HIV bioactives, efavirenz (EFV), tenofovir (TDF) and emtricitabine (FTC). HA was strategically employed based on its capability of entrapping both hydrophilic and hydrophobic drugs. PQ10 contributed towards the system’s swellability in aqueous media. The HA-PQ10 PEC was responsible for retarding drug release therefore it behaved as a drug reservoir. Validation of HA-PQ10 complexation was carried out by synthesizing the HA-PQ10 polyelectrolyte complex (PEC) in aqueous media at pH 6, 7 and 8. The complexation yielded fibrilla and porous PECs. The PEC formation was attributed to ionic interactions between the quaternary ammonium centres (PQ10) and carboxylic groups (HA). The PECs were determined to be amorphous in nature and exhibited good biocompatibility when tested for cytotoxicity in human adenocarcinoma cell line (Caco2). The model drug, efavirenz (EFV) was loaded into HA-PQ10 using the complexation-precipitation (C-P) technique. The resultant EFV-loaded HA-PQ10 was compared to benchtop extrudates manufactured using the extrusion-spheronization (E-S) process. Assessment of the EFV saturation solubility and intestinal permeability showed EFV solubility and permeability enhancement of 14.14±2.81% and 61.24±6.92% respectively. The properties were compared to those of a marketed comparator product. Loading RTV into the optimized HA-PQ10 further validated the solubility and permeability enhancing properties in the BCS class IV drug as well. The extrudates performed superiorly compared to the formulation synthesized by C-P. The E-S technique was utilized to optimize HA-PQ10 based on drug release and intestinal permeation enhancement. The optimal HA-PQ10 was employed for 3DP of EFV-loaded HA-PQ10 into an oral tablet formulation. It was imperative to add cellulose acetate phthalate (CAP) to enhance the 3D-Printability of the HA-PQ10. CAP made the synthesized delivery system pH responsive and drug release results showed that most of the release occurred under intestinal conditions. The EFV-loaded 3DP tablet was compared to a tablet synthesized by direct compression. 3DP was more porous, less dense and more swellable than the direct compression tablet. These remarkable differences were attributed to the tableting method. 3DP leads to the formation of solid bridges between particles as the sludge (ink) undergoes extrusion and drying process. The direct compression technique involves axial powder compaction at high pressures which force particles to interact through Van der Waals forces or hydrogen bond formation. High drug loading of EFV was achieved and the tablet was further optimized to manufacture the ‘controlled release tritherapeutic tablet’, CRTT, a fixed dose combination (FDC) consisting of EFV, TDF and FTC. In vivo studies were conducted in large white pigs and CRTT absorption was compared to a marketed FDC, Atripla®. There was sustained release of EFV, TDF and FTC from CRTT and this was validated by the long residence times determined from pharmacokinetic analysis. EFV was maintained within the therapeutic index of the drug during the 24 hour study. Through this study, 3DP proved to be a technology with potential for manufacturing novel formulations. As more research is underway in the 3DP field, it can only be appreciated that its scope of use will continue to grow and restructure pharmaceutical manufacturing processes. / LG2018

Thesis (Ph. D.)--University of Virginia, 2008. / Title from title page. Includes bibliographical references. Also available online through Digital Dissertations.

Introdução: A manutenção da boa adesão aos medicamentos antirretrovirais é considerada fundamental para a terapia de pacientes com HIV/Aids, pois falhas no seguimento da prescrição podem levar ao comprometimento de toda a terapia, desenvolvimento de resistência viral e consequente redução nas opções de tratamento. Nas crianças, a adesão plena torna-se mais relevante se forem considerados os diferentes graus de maturidade do sistema imunológico no momento da infecção pelo HIV, tornando, assim, fundamental a avaliação da adesão nesta população. Objetivos: Analisar a taxa de adesão ao tratamento antirretroviral em crianças e adolescentes com HIV/Aids. Métodos: Este estudo transversal, aninhado à coorte de crianças e adolescentes com HIV/Aids atendidas no ambulatório do Instituto da Criança, analisou 101 pacientes. Os dados dos pacientes foram obtidos por meio de questionários sobre as características sociodemográficas e clínicas, sobre a aderência, além de escalas de expectativa de auto-eficácia. A taxa de adesão foi calculada classificando como aderentes aqueles pacientes que tomaram 95 por cento ou mais das doses referidas.  A análise descritiva (média, desvio-padrão, mediana e proporções) foi realizada para caracterizar a população do estudo e o teste de Wilcoxon foi utilizado para comparação das médias da escala de auto-eficácia dos pais/cuidadores e pacientes acima de 11 anos. Resultados: A taxa de adesão ao tratamento antirretroviral foi de 93,1 por cento (IC = [88,7;94,4]). Houve 7 pacientes que apresentaram má adesão. Os medicamentos antirretrovirais mais utilizados foram lopinavir (51,5 por cento ), lamivudina (43,6 por cento ) e Biovir® (associação de lamivudina e zidovudina) (28,7 por cento ). Conclusão: Alta taxa de adesão ao tratamento antirretroviral por crianças e adolescentes pode ser atingida, independentemente de seu perfil sociodemográfico e/ou 95 por cento de seus cuidadores, por meio do cuidado que a equipe multiproffisional dedica aos pacientes / Introduction: Maintaining good adherence to antiretroviral drugs is considered critical to drug therapy of patients with HIV/Aids, because prescription noncompliance can compromise the entire therapy, lead to the development of viral resistance and consequent reduction in treatment options. In children, full adherence becomes more relevant if different degrees of maturity of the immune system at the time of HIV infection are considered, thereby making the assessment of adherence required in this population. Objectives: To analyze adherence rate to antiretroviral treatment in children and adolescents with HIVAids. Methods: This cross-sectional study nested in a cohort of children and adolescents with HIVAids followed up at the Instituto da Criança, assessed 101 patients. Patient data were obtained by means of questionnaires on sociodemographic and clinical characteristics, adherence and self-efficacy expectancy scales. The adherence rate was calculated by classifying as adherents those patients who had taken 95 per cent or more of these doses. The descriptive analysis (mean, standard deviation, median and proportions) was performed to characterize the study population and the Wilcoxon test was used for the correlation between the scale of self-efficacy of parents/caregivers and patients over 11 years old. Results: The adherence rate to antiretroviral treatment was 93.1 per cent (CI = [88.7;94.4]). There were 7 patients who have poor adherence. Antiretroviral drugs frequently used were lopinavir (51.5 per cent ), lamivudine (43.6 per cent ) and Biovir 95 per cent TM (lamivudine plus zidovudine) (28.7 per cent ). Conclusions: High rate of adherence to antiretroviral treatment for children and adolescents can be met, regardless of their demographic profile and/or of their caregivers, through the care that the multiprofessional team dedicated to patients

Introdução: A manutenção da boa adesão aos medicamentos antirretrovirais é considerada fundamental para a terapia de pacientes com HIV/Aids, pois falhas no seguimento da prescrição podem levar ao comprometimento de toda a terapia, desenvolvimento de resistência viral e consequente redução nas opções de tratamento. Nas crianças, a adesão plena torna-se mais relevante se forem considerados os diferentes graus de maturidade do sistema imunológico no momento da infecção pelo HIV, tornando, assim, fundamental a avaliação da adesão nesta população. Objetivos: Analisar a taxa de adesão ao tratamento antirretroviral em crianças e adolescentes com HIV/Aids. Métodos: Este estudo transversal, aninhado à coorte de crianças e adolescentes com HIV/Aids atendidas no ambulatório do Instituto da Criança, analisou 101 pacientes. Os dados dos pacientes foram obtidos por meio de questionários sobre as características sociodemográficas e clínicas, sobre a aderência, além de escalas de expectativa de auto-eficácia. A taxa de adesão foi calculada classificando como aderentes aqueles pacientes que tomaram 95 por cento ou mais das doses referidas.  A análise descritiva (média, desvio-padrão, mediana e proporções) foi realizada para caracterizar a população do estudo e o teste de Wilcoxon foi utilizado para comparação das médias da escala de auto-eficácia dos pais/cuidadores e pacientes acima de 11 anos. Resultados: A taxa de adesão ao tratamento antirretroviral foi de 93,1 por cento (IC = [88,7;94,4]). Houve 7 pacientes que apresentaram má adesão. Os medicamentos antirretrovirais mais utilizados foram lopinavir (51,5 por cento ), lamivudina (43,6 por cento ) e Biovir® (associação de lamivudina e zidovudina) (28,7 por cento ). Conclusão: Alta taxa de adesão ao tratamento antirretroviral por crianças e adolescentes pode ser atingida, independentemente de seu perfil sociodemográfico e/ou 95 por cento de seus cuidadores, por meio do cuidado que a equipe multiproffisional dedica aos pacientes / Introduction: Maintaining good adherence to antiretroviral drugs is considered critical to drug therapy of patients with HIV/Aids, because prescription noncompliance can compromise the entire therapy, lead to the development of viral resistance and consequent reduction in treatment options. In children, full adherence becomes more relevant if different degrees of maturity of the immune system at the time of HIV infection are considered, thereby making the assessment of adherence required in this population. Objectives: To analyze adherence rate to antiretroviral treatment in children and adolescents with HIVAids. Methods: This cross-sectional study nested in a cohort of children and adolescents with HIVAids followed up at the Instituto da Criança, assessed 101 patients. Patient data were obtained by means of questionnaires on sociodemographic and clinical characteristics, adherence and self-efficacy expectancy scales. The adherence rate was calculated by classifying as adherents those patients who had taken 95 per cent or more of these doses. The descriptive analysis (mean, standard deviation, median and proportions) was performed to characterize the study population and the Wilcoxon test was used for the correlation between the scale of self-efficacy of parents/caregivers and patients over 11 years old. Results: The adherence rate to antiretroviral treatment was 93.1 per cent (CI = [88.7;94.4]). There were 7 patients who have poor adherence. Antiretroviral drugs frequently used were lopinavir (51.5 per cent ), lamivudine (43.6 per cent ) and Biovir 95 per cent TM (lamivudine plus zidovudine) (28.7 per cent ). Conclusions: High rate of adherence to antiretroviral treatment for children and adolescents can be met, regardless of their demographic profile and/or of their caregivers, through the care that the multiprofessional team dedicated to patients

Translocation of viral integrase into nucleus is a critical precondition of integration during the life cycle of HIV, a causative agent of Acquired Immunodeficiency Syndromes (AIDS). It has been considered as an important target for the drug development to treat AIDS. In order to understand the detailed mechanisms of integrase-host cell protein complex interactions, we cloned HIV-1 integrase-EGFP into pTRE2hyg as visible tag to monitor the translocation process. When transiently transfected this vector into Tet-off ready HeLa cells, the EGFP: integrase is mainly localized in the nucleus. It has been hypothesized that any drugs that can inhibit the translocation process are novel class of drugs for AIDS treatment. More than 30000 synthetic compounds and 80000 natural products were screened by virtual screening. A total of 34 compounds were obtained and screened for their ability to block the nuclear entry of HIV-1 integrase by monitoring the EGFP fluorescence in the cells by high-throughput live cell imaging. Eight synthetic compounds (DW-IN4, DW-IN5, DW-IN6, DW-IN9, DW-IN15, DW-IN16, DW-IN17, DW-IN21) and one natural product (DW-IN719) were found to block integrase translocation significantly. According to our screening result, six compounds (INNB-1, INNB-2, INNB-3, INNB-4, INNB-5, INNB-6) were designed and synthesized. INNB-1 and INNB-2 had significant inhibition on integrase nuclear translocation. DW-IN6, DWIN719, INNB-1, INNB-2, INNB-3 and INNB-4, showed significant inhibition on P24 production in live virus assay. DW-IN6, INNB-1, INNB-2, INNB-3 and INNB-4 showed significant syncitia formation inhibition in live virus assay. Six compounds (KM7, KM8, KM14, KM30, KM37, KM79) from Kunming were screened as integrase nuclear translocation inhibitors. Using similar cell imaging techniques, we have cloned the GFP-tagged chemokine receptor CXCR4 using the lentivirus transfection system. CXCR4 receptor is a critical co-receptor in CD4 positive lymphocytes mediating the fusion of HIV into the CD4 positive cells. CXCR4-GFP was over-expressed in 293T cells and the results showed that GFP:CXCR4 receptor is expressed at the plasma membrane of the cells. These cells have been used to monitor the blockage of CXCR4 receptor internalization for drug development. Four compounds (KX128, KX166, KX171, KX180) from Kunming showed CXCR4 internalization blockage in imaging assay. The interaction of these compounds with CXCR4 was predicted by molecular docking. KX128 showed significant HIV inhibition in live virus assays. / Gu, Wangang. / Advisers: Pang Chui Shaw; David Chi Cheong Wan. / Source: Dissertation Abstracts International, Volume: 73-06, Section: B, page: . / Thesis (Ph.D.)--Chinese University of Hong Kong, 2011. / Includes bibliographical references (leaves 165-179). / Electronic reproduction. Hong Kong : Chinese University of Hong Kong, [2012] System requirements: Adobe Acrobat Reader. Available via World Wide Web. / Electronic reproduction. [Ann Arbor, MI] : ProQuest Information and Learning, [201-] System requirements: Adobe Acrobat Reader. Available via World Wide Web. / Abstract also in Chinese.

核糖體抑活蛋白 (RIPs) 屬於糖苷酶的一種，能從23S或28S核糖體核糖核酸中的sarcin-ricin環(sarcin-ricin loop, SRL)移除一個特定的腺嘌呤，引致核糖體失效。由於核糖體蛋白協助RIP到達SRL，因此它們對RIP的核糖體特認性是極大的重要。雖然各RIPs的份子結構及催化活動非常相似，它們的核糖體特認性和效力存著很大的迥異。此外，現時還未能找出只有少數RIPs能同時抑制原核和真核生物的核糖體的原因。我們試圖從玉米核糖體抑活蛋白 (Maize RIP) 和真核生物的核糖體以及志賀毒素 (Shiga toxin) 和原核生物的核糖體的相互作用的研究中去解釋以上的現象。 / 我們發現Maize RIP提供一個前所未見的區域與核糖體蛋白P2結合，並展示RIPs的結構大大限制了它們與核糖體蛋白的相互作用的性質和強度，從而影響RIPs在核糖體上的效力。另外，我們發現志賀毒素跟細菌的核糖體的相互作用比跟真核生物核糖體的相互作用弱，並可能跟細菌核糖體蛋白L7/L10有交聯。我們在蓖麻毒蛋白 (Ricin) 的碳端 (C-terminus) 加上人類免疫缺陷病毒-(HIV-1) 蛋白酶特認的肽以增加 ricin 對HIV-1蛋白酶的特認性，並希望此研究結果有助於應用相類的策略到其他RIPs上。 / Ribosome-inactivating proteins (RIPs) are N-glycosidases that inactivate ribosome by removing a specific adenine from the sarcin-ricin loop (SRL) of 23S or 28S ribosomal RNA. Ribosomal proteins are critical for determining the ribosome specificity of RIPs as they assist RIPs to get access to the SRL. Ribosome specificity and potency of RIPs are highly varied although their tertiary structures and catalytic depurination are highly alike. Moreover, it is still unsolved why only a few RIPs acquiring the ability to inhibit both prokaryotic and eukaryotic ribosomes. We attempted to elucidate the phenomena by investigating the interactions of maize RIP with eukaryotic ribosome and shiga toxin with prokaryotic ribosome. / Here we showed maize RIP presents a novel docking site to interact with ribosomal protein P2 and demonstrated the structure of RIPs imposes a large constraint on the nature and strength of the interaction with ribosomal protein which in turn affect the potency of RIPs on the ribosome. Shiga toxin was found to interact with prokaryotic ribosome weaker than the eukaryotic ribosome and crosslinked to the bacterial ribosomal protein L7/L10. Additionally, we increased the HIV-1 specificity of ricin A chain by incorporating the HIV-1 protease specific peptide to the C-terminus of the toxin and hope our findings would help to extend similar scheme to other RIPs in the future. / Detailed summary in vernacular field only. / Detailed summary in vernacular field only. / Wong, Yuen-Ting. / Thesis (Ph.D.)--Chinese University of Hong Kong, 2012. / Includes bibliographical references (leaves 146-159). / Electronic reproduction. Hong Kong : Chinese University of Hong Kong, [2012] System requirements: Adobe Acrobat Reader. Available via World Wide Web. / Abstract also in Chinese. / Acknowledgements --- p.i / Abstract --- p.ii / 摘要 --- p.iii / Table of Contents --- p. iv - viii / Chapter Chapter One --- Introduction of ribosome-inactivating proteins / Chapter 1.1 --- Nomenclature and distribution of ribosome-inactivating proteins --- p.1 / Chapter 1.2 --- Enzymatic activity of ribosome-inactivating proteins and their biological role --- p.2 / Chapter 1.3 --- Structure and catalytic centre of ribosome-inactivating proteins --- p.3 / Chapter 1.4 --- Ribosome specificity of RIPs and their interaction with ribosome --- p.5 / Chapter 1.5 --- Cytotoxicity and antiviral activity of ribosome-inactivating proteins --- p.6 / Chapter 1.6 --- Antiviral activity of RIPs --- p.9 / Chapter 1.7 --- Cellular trafficking of ribosome-inactivating proteins --- p.10 / Chapter 1.8 --- Application and therapeutic use of ribosome-inactivating proteins --- p.10 / Chapter 1.9 --- Evolution of RIPs --- p.11 / Chapter 1.10 --- Other activities of RIPs --- p.12 / Chapter Chapter Two --- Characterization of the interaction between RIPs and rat liver ribosome and its correlation with the potency of RIPs / Chapter 2.1 --- Introduction --- p.12 / Chapter 2.1.1 --- Nature of interaction between RIPs and eukaryotic ribosome --- p.12 / Chapter 2.1.2 --- RIPs interact with specific ribosomal proteins --- p.15 / Chapter 2.1.3 --- RIPs demonstrate different specificity towards ribosomes --- p.16 / Chapter 2.1.4 --- Introduction of maize RIP --- p.20 / Chapter 2.1.5 --- Interaction between maize RIP and ribosome --- p.22 / Chapter 2.2 --- Objectives and significance --- p.22 / Chapter 2.3 --- Materials and Methods / Chapter 2.3.1 --- Cloning and site-directed mutagenesis of RIPs --- p.23 / Chapter 2.3.2 --- Protein expression and purification --- p.23-26 / Chapter 2.3.2.1 --- Maize RIP and variants / Chapter 2.3.2.2 --- His-myc-MOD and His-MOD / Chapter 2.3.2.3 --- Trichosanthin (TCS) / Chapter 2.3.2.4 --- Shiga toxin chain A [E167AE170A] (StxA) / Chapter 2.3.2.5 --- Ricin chain A (RTA) / Chapter 2.3.2.6 --- Pokeweed antiviral protein (PAP) / Chapter 2.3.2.7 --- C-terminal His-tagged MOD, TCS and RTA / Chapter 2.3.2.8 --- His-SUMO-protease / Chapter 2.3.2.9 --- P2 and its variants / Chapter 2.3.2.10 --- Protein concentration and storage / Chapter 2.3.3 --- Purification of rat liver ribosome --- p.26 / Chapter 2.3.4 --- In vitro pull-down assay with ribosome --- p.27 / Chapter 2.3.5 --- On-resin crosslinking and mass spectrometry --- p.27 / Chapter 2.3.6 --- Crosslinking assay and western blotting --- p.28 / Chapter 2.3.7 --- In vitro pull-down assay with P2 --- p.29 / Chapter 2.3.8 --- In vitro pull-down assay with P2 and its variants --- p.29 / Chapter 2.3.9 --- Surface Plasmon Resonance --- p.29 / Chapter 2.3.10 --- N-glycosidase activity assay and quantitative PCR --- p.30 / Chapter 2.3.11 --- Cytotoxicity on 293T --- p.31 / Chapter 2.3.12 --- Cellular uptake of RIPs and western blotting --- p.32 / Chapter 2.4 --- Results / Chapter 2.4.1 --- In vitro pull-down assay with ribosome --- p.32 / Chapter 2.4.2 --- On-resin crosslinking and mass spectrometry of crosslinked proteins --- p.37 / Chapter 2.4.3 --- Crosslinking assay and western blotting --- p.40 / Chapter 2.4.4 --- In vitro pull-down assay with P2 --- p.43 / Chapter 2.4.5 --- Sensorgram of binding between P2 and Maize RIP variants --- p.44 / Chapter 2.4.6 --- N-glycosidase activity of maize RIP variants --- p.45 / Chapter 2.4.7 --- Cytotoxicity of maize RIP variants --- p.48 / Chapter 2.4.8 --- In vitro pull-down assay with P2 and its variants --- p.49 / Chapter 2.4.9 --- Surface Plasmon Resonance of P2 and various RIPs --- p.52 / Chapter 2.4.10 --- N-glycosidase activity assay and quantitative PCR --- p.55 / Chapter 2.4.11 --- Cytotoxicity of RIPs to 293T --- p.57 / Chapter 2.5 --- Discussion --- p.59 / Chapter 2.6 --- Conclusion --- p.72 / Chapter Chapter Three --- Identifying prokaryotic ribosomal protein(s) interacting with shiga toxin / Chapter 3.1 --- Introduction / Chapter 3.1.1 --- Background of shiga toxin --- p.74 / Chapter 3.1.2 --- Trafficking and activation of shiga toxin --- p.75 / Chapter 3.1.3 --- Intoxication by Shiga toxin --- p.76 / Chapter 3.1.4 --- Dual specificity on ribosome --- p.77 / Chapter 3.2 --- Objectives and significance --- p.78 / Chapter 3.3 --- Materials and methods / Chapter 3.3.1 --- Cloning of Shiga toxin and ribosomal proteins --- p.79 / Chapter 3.3.2 --- Expression and purification --- p.79-80 / Chapter 3.3.2.1 --- His-SUMO StxA, His-StxA, and His-StxA [E167Q] / Chapter 3.3.2.2 --- Ribosomal proteins / Chapter 3.3.3 --- Isolation of E. coli ribosome and rat liver ribosome --- p.80 / Chapter 3.3.4 --- Pull-down assay of prokaryotic and eukaryotic ribosome --- p.81 / Chapter 3.3.5 --- Size-exclusion chromatography of RIPs and prokaryotic ribosome --- p.81 / Chapter 3.3.6 --- Pull-down assay of StxA with HepG2 and C41 lysate --- p.82 / Chapter 3.3.7 --- Two-dimensional electrophoresis --- p.82 / Chapter 3.3.8 --- Mass spectrometric analysis of pull-down assay --- p.83 / Chapter 3.3.9 --- Crosslinking of StxA with r-proteins --- p.84 / Chapter 3.4 --- Results / Chapter 3.4.1 --- Cloning of wild-type shiga toxin --- p.84 / Chapter 3.4.2 --- Pull-down with prokaryotic and eukaryotic ribosome --- p.85 / Chapter 3.4.3 --- Size-exclusion chromatography of RIPs and prokaryotic ribosome --- p.88 / Chapter 3.3.4 --- Pull-down assay of StxA with HepG2 and C41 lysates --- p.90 / Chapter 3.4.5 --- Crosslinking of StxA with r-proteins --- p.97 / Chapter 3.5 --- Discussion and conclusion --- p.99 / Chapter Chapter Four --- Engineering ricin A chain for increasing its specificity toward Human Immunodeficiency Virus (HIV) / Chapter 4.1 --- Introduction --- p.104 / Chapter 4.1.1 --- Human immunodeficiency virus --- p.104 / Chapter 4.1.2 --- Current drugs for HIV --- p.105 / Chapter 4.1.3 --- Anti-HIV mechanism of RIPs --- p.105 / Chapter 4.1.4 --- Engineering cytotoxic protein into HIV-1 specific toxin --- p.107 / Chapter 4.2 --- Objectives and significance --- p.109 / Chapter 4.3 --- Materials and methods / Chapter 4.3.1 --- Design and cloning of RTA HIV-1 specific variants --- p.109 / Chapter 4.3.2 --- Cloning, expression and purification of ricin variants --- p.112 / Chapter 4.3.3 --- Purification of HIV-1 protease --- p.112 / Chapter 4.3.4 --- HIV-1 protease induced cleavage of RTA variants --- p.113 / Chapter 4.3.5 --- Cytotoxicity on 293T and JAR --- p.114 / Chapter 4.4 --- Results / Chapter 4.4.1 --- Purity check of RTA variants --- p.114 / Chapter 4.4.2 --- HIV-1 protease induced cleavage of RTA variants --- p.115 / Chapter 4.4.3 --- Cytotoxicity on 293T and JAR --- p.119 / Chapter 4.5 --- Discussion --- p.124 / Chapter 4.6 --- Conclusion --- p.126 / Concluding remarks and future prospect --- p.127 / Appendices / Appendix 1 --- p.128 - 132 / Appendix 2 --- p.133 - 134 / Appendix 3 --- p.135 - 138 / Appendix 4 --- p.139 - 145 / Bibliography --- p.146 - 159